Mental Retardation Clinical Trial
Official title:
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
OBJECTIVES: I. Determine differences between persons with repetitive behavior disorders and
matched controls on measures of motor control relevant to basal ganglia pathophysiology.
II. Determine the efficacy of bromocriptine, a dopamine agonist, in the treatment of
stereotyped behavior and related behavior disorders.
III. Determine the efficacy of sertraline hydrochloride, a selective serotonin uptake
inhibitor, in the treatment of repetitive behavior disorders.
IV. Identify behavioral, environmental, and biological variables with differential drug
treatment response.
PROTOCOL OUTLINE: Motor slowness (bradykinesia) and motor control are tested in repetitive
behavior disorder patients and matched controls. Group differences reflecting alterations in
basal ganglia dopamine function are compared.
Behavioral assessments are conducted on each patient by trained observers. Assessments are
taken at baseline and during the maintenance phase of drug treatment described below.
The efficacy of bromocriptine in the treatment of stereotypy and self-injury is determined
in a randomized, double blind, placebo controlled, crossover study extending over 20 weeks.
Cohorts of 6 to 8 patients first enter into a single blind placebo phase, followed by double
blind treatment with placebo or bromocriptine. The crossover manipulation entails a
titration phase, a maintenance phase, then a final single blind placebo condition.
The same experimental design is used to determine the efficacy of sertraline or placebo in
the treatment of stereotypy and concomitant self injury and compulsions. Duration of study
is 26 weeks.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02791321 -
Fragility Assessment in Adults With ADHD and Mental Retardation
|
N/A | |
| Recruiting |
NCT01908400 -
Safety and Efficacy of BMMNCin Patients With Mental Retardation
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02245724 -
Stem Cell Therapy in Mental Retardation
|
Phase 1 | |
| Completed |
NCT00156221 -
MR Scanning of Very Young Children With Severe Developmental Disorders
|
N/A | |
| Recruiting |
NCT00491478 -
Repetitive Behavior Disorders in People With Severe Mental Retardation
|
Phase 3 | |
| Terminated |
NCT02797418 -
"Cognitus & Moi": a New Cognitive Remediation Tool
|
N/A | |
| Completed |
NCT00758108 -
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
|
||
| Completed |
NCT01430845 -
Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay
|
||
| Not yet recruiting |
NCT02214745 -
Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community
|
N/A | |
| Active, not recruiting |
NCT00552526 -
Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
|
Phase 4 | |
| Completed |
NCT02943304 -
Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
|
||
| Completed |
NCT00491894 -
Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
|
Phase 3 | |
| Completed |
NCT01291238 -
School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability.
|
N/A | |
| Completed |
NCT01456910 -
Resistance Training Program, Labor Inclusion, Intellectual Disability
|
N/A | |
| Completed |
NCT00065273 -
Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay
|
Phase 3 | |
| Active, not recruiting |
NCT00065936 -
Self-Injury: Diagnosis and Treatment
|
Phase 3 | |
| Completed |
NCT00506259 -
Treatment Strategies for Children With Smith-Magenis Syndrome
|
Phase 1 | |
| Not yet recruiting |
NCT05442229 -
A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years
|
||
| Active, not recruiting |
NCT06370793 -
Ningbo Severe Mental Disorders Cohort
|
||
| Completed |
NCT01517048 -
Brain-Derived Neurotrophic Factor in Obesity and Brain Function
|